nnc172-2021
Congenital Bleeding Disorder
Novo Nordisk A/SPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Congenital Bleeding Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Turoctocog Alfa Novo Nordisk A/S | Phase 4 | A |
Eptacog Alfa Novo Nordisk A/S | Phase 4 | A |
Turoctocog Alfa Pegol Novo Nordisk A/S | Phase 3 | A |
Nonacog Beta Pegol Novo Nordisk A/S | Phase 3 | A |
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX Assiut University | Phase 4 | BB |
View all 18 →
Same molecule, other indications
nnc172-2021 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →